7:16 AM ET
8-K
Investor Presentation
Sagimet Biosciences Investor Presentation
Sagimet Biosciences Inc. has updated its corporate investor presentation, which will be used by management in upcoming meetings with investors. The presentation, filed as Exhibit 99.1, provides an overview of the company's novel therapeutics targeting metabolic dysfunction, including its lead candidate denifanstat.